| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the latest quarter, 9 analysts provided ratings for Intellia Therapeutics (NASDAQ:NTLA), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 2 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 0 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Intellia Therapeutics, revealing an average target of $33.89, a high estimate of $60.00, and a low estimate of $10.00. This current average has decreased by 12.11% from the previous average price target of $38.56.
A comprehensive examination of how financial experts perceive Intellia Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Geulah Livshits | Chardan Capital | Lowers | Buy | $60.00 | $68.00 |
| Luca Issi | RBC Capital | Lowers | Outperform | $21.00 | $25.00 |
| Yanan Zhu | Wells Fargo | Lowers | Overweight | $45.00 | $50.00 |
| Mitchell S. Kapoor | HC Wainwright & Co. | Lowers | Buy | $25.00 | $30.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $30.00 | $30.00 |
| Whitney Ijem | Canaccord Genuity | Lowers | Buy | $54.00 | $74.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $30.00 | $30.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $30.00 | $30.00 |
| David Nierengarten | Wedbush | Maintains | Neutral | $10.00 | $10.00 |
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Intellia Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Intellia Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3M period, Intellia Therapeutics showcased positive performance, achieving a revenue growth rate of 104.76% as of 30 June, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Intellia Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -710.81%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Intellia Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -13.54%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -10.74%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.14.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: NTLA
